Onchocerciasis Treatment Global Market Report 2025

The onchocerciasis treatment market size has grown strongly in recent years. It will grow from $1.03 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period is due to an increase in patients suffering from eye-associated issues, an increase in parasitic infections, an increase in the number of targeted treatment centers, a rise in education campaigns, and an increase in the geriatric population.

The onchocerciasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period is due to factors such as rising prevalence in endemic regions, rising demand for surgical procedures, expanding healthcare infrastructure, growing prevalence of chronic diseases, and increasing healthcare investments. Major trends in the forecast period include a shift towards single-dose regimens, advancements in macrocyclic lactone formulations, the emergence of Wolbachia-targeting therapies, the integration of artificial intelligence (AI) in drug discovery, and the development of pediatric-specific treatments.

The increasing number of individuals suffering from eye-related conditions is expected to drive the growth of the onchocerciasis treatment market. These conditions encompass a range of vision and ocular health issues, including infections, injuries, and chronic diseases such as glaucoma and cataracts. A key contributor to this rise is the extended screen time and prolonged exposure to digital devices. Onchocerciasis treatment plays a crucial role in preventing and managing vision loss by eliminating the parasitic infection responsible for inflammation and ocular damage. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 20.5 million Americans over the age of 40 have cataracts in at least one eye, representing 17.2% of that age group. The number is expected to reach nearly 30 million by 2028. Consequently, the growing prevalence of eye-related issues is boosting the demand for onchocerciasis treatment.

The increasing need for surgical procedures is also contributing to the growth of the onchocerciasis treatment market. Surgical procedures involve medical interventions to remove or repair tissues affected by disease and are often required when drug treatments fail or complications pose long-term health risks. The progression of onchocerciasis to advanced stages in some patients necessitates surgical intervention to prevent permanent damage such as vision loss or disfigurement. In response, healthcare systems are enhancing their surgical capabilities and adopting advanced techniques, thereby supporting market expansion. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS) reported that nearly 35 million aesthetic procedures were performed globally in 2023, marking a 3.4% increase from the previous year. Surgical procedures rose by 5.5%, with more than 15.8 million performed by plastic surgeons. This growing demand for surgeries is reinforcing the onchocerciasis treatment market.

Leading companies in the onchocerciasis treatment market are prioritizing the development of innovative antiparasitic drugs to enhance treatment outcomes and accessibility. These drugs target parasites such as worms and protozoa, which are responsible for infections like onchocerciasis. In December 2024, Medicines Development for Global Health (MDGH), an Australian non-profit biopharmaceutical company, received approval from the Ghana Food and Drugs Authority for Moxidectin 2 mg oral tablets, intended for the treatment of river blindness in individuals aged four and above. This approval paves the way for community-wide mass drug administration initiatives in Ghana, utilizing moxidectin's superior efficacy and extended duration of action compared to ivermectin. Through this initiative, MDGH aims to increase access to a more effective treatment, supporting widespread implementation in endemic areas.

Major players in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos - Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, and Cerata Pharmaceuticals Inc.

North America was the largest region in the onchocerciasis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onchocerciasis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the onchocerciasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Onchocerciasis treatment encompasses medical and therapeutic interventions aimed at managing and eliminating infections caused by Onchocerca volvulus, the parasite responsible for river blindness - a disease that primarily impacts the skin and eyes. The key objective of treatment is to eradicate the microfilariae (immature larvae) to reduce transmission, alleviate symptoms, and lower the risk of vision impairment.

The primary drugs used in onchocerciasis treatment include ivermectin, doxycycline, albendazole, and moxidectin. Ivermectin is an antiparasitic agent employed in treating several parasitic diseases, including onchocerciasis (river blindness), by targeting and killing the parasite’s larvae (microfilariae). Treatment approaches consist of mass drug administration (MDA) and targeted therapies, utilizing various forms of administration such as oral, injectable, and topical options. These treatments are distributed through hospital pharmacies, retail pharmacies, and online platforms, and they cater to end-users including hospitals and clinics, home-based care settings, and government as well as non-governmental initiatives.

The onchocerciasis treatment market research report is one of a series of new reports that provides onchocerciasis treatment market statistics, including the onchocerciasis treatment industry global market size, regional shares, competitors with the onchocerciasis treatment market share, detailed onchocerciasis treatment market segments, market trends, opportunities, and any further data you may need to thrive in the onchocerciasis treatment industry. This onchocerciasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The onchocerciasis treatment market consists of revenues earned by entities providing services such as mass drug administration (MDA) campaigns, community-based health outreach, disease surveillance and diagnostics, vector control initiatives, and public health education. The market value includes the value of related goods sold by the service provider or included within the service offering. The onchocerciasis treatment market also includes sales of antiparasitic drugs, diagnostic kits, drug delivery tools, and protective supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.